Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone

Table 5

Adverse events during treatment.

	Gastrointestinal reactions	Ototoxicity	Neurotoxicity	Others	AEs
Control group (n = 40)	4	1	2	2	9 (22.50)
Study group (n = 40)	3	2	3	4	12 (30.00)
χ^2					0.581
					0.446

AEs, adverse events.